• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Neurology

Viral vector based gene therapies show promise for treating focal epilepsy [PreClinical]

byRadhika Agarwal
July 29, 2018
in Neurology, Pediatrics, Preclinical
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Seizures are often associated with accumulation of extracellular glutamate due to the synchronous discharges of excitatory neurons.

2. Treatment of rats with a lentiviral plasmid encoding a glutamate-gated chloride channel was able to decrease focal seizure activity by hyperpolarizing neurons and decreasing their effective membrane resistance.

Evidence Rating Level: 2 (Good)

Study Rundown: Despite the development of several anti-epileptic medications, one-third of patients with epilepsy continue to have seizures. Current antiepileptic drugs have a narrow therapeutic window and require close monitoring. Surgical resection of epileptogenic foci is restricted to cases in which the foci are far enough away from areas involved in motor or sensory processing. For patients with treatment-refractory focal seizures, molecular strategies aimed at decreasing the effect of glutamate accumulation near epileptogenic foci in the brain, may provide a new and potentially more effective approach at reducing seizure activity.

In this study, a plasmid was designed to carry the sequence of a glutamate-gated chloride channel (GluCl) from C. elegans. A residue in the α subunit of the channel was mutated to enhance the channel’s glutamate sensitivity (eGluCl). Expression of eGluCl was placed under the control of the human CaMKIIα promoter in order to bias expression of eGluCl to excitatory neurons. The plasmid was delivered to neurons via lentivirus, and the eGluCl channel was found to be stably expressed mainly at non-synaptic sites on neuronal cell surfaces.

The ability of the eGluCl treatment to attenuate seizure development was assessed in rodent models, in which seizures were induced in two ways: (1) with intracortical injection of the chemoconvulsant pilocarpine, which acutely induces seizure activity or (2) with tetanus-toxin injection into the visual cortex which results in chronic spontaneous seizures over the course of several weeks. Administration of eGluCl was found to decrease acute chemoconvulsant-induced seizures, as well as decrease the absolute number of seizures in the model of chronic focal neocortical epilepsy. Additionally, the eGluCl treatment itself was found to not have a major effect on normal brain behavioral function, as assessed by two tests of motor coordination, suggesting that gene therapy with eGluCl may be well-tolerated. While further studies in higher-order primates will be necessary to better predict its effectiveness and off-target effects in humans, the ability of eGluCl therapy to selectively inhibit neurons in response to increases in extracellular glutamate concentrations represents a promising new approach to focal epilepsy that remains refractory to other forms of treatment.

RELATED REPORTS

Praxis Precision’s relutrigine reduces seizures in rare epileptic disorders in phase 2 clinical trials

Artificial intelligence may improve the accuracy of physicians’ electroencephalogram interpretations

Topiramate for prenatal antiseizure therapy is not associated autism spectrum disorder

Click here to read about the eGluCl therapy for focal epilepsy

Relevant Reading: Novel approaches to epilepsy treatment

In-Depth [animal study]: A wild-type glutamate-gated chloride channel from C. elegans GluCl was codon optimized for human expression (GluCl) and the L9’F mutation to increase glutamate sensitivity (eGluCl) was inserted with a QuikChange II kit from Agilent. The increased sensitivity of the eGluCl under the control of the human CamKII-α promoter was confirmed with voltage clamp recordings using a mouse neuroblastoma cell line (Neuro-2a).

In order to induce seizure activity, male Sprague Dawley rats were cannulated either in the forelimb area of the right primary motor cortex or in the right visual cortex, and an ECoG transmitter was implanted to allow for wireless telemetry readings. For the chemoconvulsant seizure model, animals were injected on four consecutive days with increasing amounts of pilocarpine solution into the primary motor cortex. Three days later, all animals were injected with either eGluCl lentivector (n = 10) or control GFP lentivector (n = 10) at the same location. Two weeks later, the chemoconvulsant injection procedure was repeated and compared to pre-treatment seizure activity. This experimental design allowed normalization of every pilocarpine-invoked seizure to its corresponding pre-treatment seizure. Animals treated with eGluCl were found to exhibit a decrease in the electrocorticogram (ECoG) coastline, an aggregate of frequency and amplitude, between the two pilocarpine injections and displayed a decrease in spike frequency (p = 0.007).

For the chronic tetanus toxin epilepsy model, animals were injected with tetanus toxin in the right visual cortex. Eleven days after tetanus toxin injection, animals were injected with eGluCl lentivector or GFP lentivector. eGluCl significantly decreased the number of subsequent seizures compared to GFP-treated animals (P < 0.001), though there was no significant difference in average seizure duration or severity between the two groups.

Image: PD

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: epilepsySeizure
Previous Post

Extreme preterm birth linked to hypertension at school age

Next Post

Comparative analysis of wounds from oral mucosa versus skin reveals novel therapeutic targets for rapid wound healing [PreClinical]

RelatedReports

Recurrent violence in post-conflict communities linked to increased mental disorders
Pharma

Praxis Precision’s relutrigine reduces seizures in rare epileptic disorders in phase 2 clinical trials

September 18, 2024
Patient Basics: Epilepsy
2 Minute Medicine

Artificial intelligence may improve the accuracy of physicians’ electroencephalogram interpretations

June 24, 2024
Neurology

Topiramate for prenatal antiseizure therapy is not associated autism spectrum disorder

May 22, 2024
FDA-approved weight loss medications associated with weight loss at one year
Chronic Disease

Dietary interventions effective in treating pediatric drug-resistant epilepsy

February 20, 2023
Next Post
Tumor-specific mutant antigens are potential targets for cancer therapy [PreClinical]

Comparative analysis of wounds from oral mucosa versus skin reveals novel therapeutic targets for rapid wound healing [PreClinical]

Incidental findings common with breast imaging, often benign

Paradigm shift in cancer treatment to targeted therapies

Hospital admission linked to reduced quality and quantity of sleep

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Living in a marginalized neighbourhood is associated with worse outcomes in patients with myocardial infarction
  • SGLT2 inhibitors may delay cognitive impairment in elderly patients with heart failure
  • Nerandomilast slows decline in FVC in idiopathic pulmonary fibrosis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.